Evidence map›Paper›PMID 36678569›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Stability Study of Parenteral N-Acetylcysteine, and Chemical Inhibition of Its Dimerization.

Nicolas Primas, Guillaume Lano, Damien Brun, Christophe Curti, Marion Sallée, Emmanuelle Sampol-Manos, Edouard Lamy, Charleric Bornet, Stéphane Burtey, Patrice Vanelle

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nicolas PrimasService Central de la Qualité et de L'information Pharmaceutiques (SCQIP), Pharmacy Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13005 Marseille, France.ORCID 0000-0002-6713-6039
Guillaume LanoCentre of Nephrology and Renal Transplantation, Hôpital de la Conception, AP-HM, 13005 Marseille, France.ORCID 0000-0003-1692-5799
Damien BrunService Central de la Qualité et de L'information Pharmaceutiques (SCQIP), Pharmacy Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13005 Marseille, France.
Christophe CurtiService Central de la Qualité et de L'information Pharmaceutiques (SCQIP), Pharmacy Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13005 Marseille, France.
Marion SalléeCentre of Nephrology and Renal Transplantation, Hôpital de la Conception, AP-HM, 13005 Marseille, France.
Emmanuelle Sampol-ManosPharmacokinetics Department, Assistance Publique-Hôpitaux Marseille (AP-HM), 13005 Marseille, France.
Edouard LamyService Central de la Qualité et de L'information Pharmaceutiques (SCQIP), Pharmacy Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13005 Marseille, France.ORCID 0000-0003-4832-2845
Charleric BornetPharmacie Usage Intérieur Hôpital Conception, Assistance Publique-Hôpitaux de Marseille (AP-HM), Hôpital de la Conception, 13005 Marseille, France.
Stéphane BurteyCentre of Nephrology and Renal Transplantation, Hôpital de la Conception, AP-HM, 13005 Marseille, France.ORCID 0000-0003-1813-7884
Patrice VanelleService Central de la Qualité et de L'information Pharmaceutiques (SCQIP), Pharmacy Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13005 Marseille, France.ORCID 0000-0002-9946-829X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parenteral N-acetylcysteine has a wide variety of clinical applications, but its use can be limited by a poor chemical stability. We managed to control parenteral N-acetylcysteine stability, and to study the influence of additives on the decrease of N-acetylcysteine degradation. First, an HPLC-UV dosing method of N-acetylcysteine and its main degradation product, a dimer, was validated and the stability without additive was studied. Then, the influence of several additives (ascorbic acid, sodium edetate, tocopherol and zinc) and of temperature on N-acetylcysteine dimerization was evaluated. Finally, the influence of zinc gluconate at different concentrations (administrable to patients) was investigated. Zinc gluconate at 62.5 µg·mL

Indexed as

N-acetylcysteineparenteral administrationstability study

Identifiers

PMID36678569
PMCPMC9860916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.